 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...6162636465666768697071...123124» |
- |||| lenvatinib / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Adverse events: Even for newer TKIs 💊 targeted therapies, like LENvatinib or CABOzantinib, besides the on-target side effects like monitoring hypertension etc. the biggest under-appreciated & intangible side effect is ✔️AESTHENIA or FATIGUE. I’ve had patients stop treatments. #Cancer #QOL (Twitter) - Mar 31, 2022
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P3 trial, Combination therapy: EMERALD-3: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (clinicaltrials.gov) - Mar 31, 2022
P3, N=525, Not yet recruiting, Sponsor: AstraZeneca
- | Oncorine (recombinant human adenovirus type 5) / Mergen Ltd., Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients with Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 31, 2022
P1b, N=25, Recruiting, Sponsor: Fudan University
- | lenvatinib / Generic mfg.
Retrospective data, Journal, Real-world evidence: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. (Pubmed Central) - Mar 30, 2022
Lenvatinib plus PD-1 blockades can provide survival benefits for HCC patients with invasion in Vp4 and the indications of lenvatinib plus pembrolizumab may be further expanded. Locoregional treatments should be considered for patients with TO ≥50% during systemic therapy.
- ||| everolimus / Generic mfg., Torisel (temsirolimus) / Pfizer, lenvatinib / Generic mfg.
Lenvatinib + ici +- temsirolimus/everolimus. We know from rcc these combinations are safe and tolerable. Now your matching score is 4/4. (Twitter) - Mar 29, 2022
- ||| Avastin (bevacizumab) / Roche, lenvatinib / Generic mfg., Nexavar (sorafenib) / Bayer, Amgen
Stk11 can be targeted with mtor inhibitor. TMB-h & SMARCA4 both can be targeted with ICI. PDGFRa can be with multiTKI like sorafenib. Tp53 can be targeted with VEGF inhibition w bevacizumab or a VEGFi from a TKI that blocks vegf and pdgfra like lenvatinib. How to safely combine? (Twitter) - Mar 29, 2022
- | lenvatinib / Generic mfg.
Journal: Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound. (Pubmed Central) - Mar 29, 2022
Locoregional treatments should be considered for patients with TO ≥50% during systemic therapy. Early blood flow evaluation by CEUS may be useful in predicting the therapeutic effect of LEN for unresectable advanced HCC.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Clinical, Journal: Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. (Pubmed Central) - Mar 29, 2022
Atez/Bev might have therapeutic potential not only as first but also later-line treatment of existing molecular target agents. In addition, this drug combination may have less influence on hepatic function during the early period, as the present patients showed a good initial therapeutic response.
- ||| lenvatinib / Generic mfg.
Clinical, Review, Journal, Adverse events: Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. (Pubmed Central) - Mar 29, 2022
Therefore, to derive maximum treatment benefit and ensure long-term disease control, lenvatinib should be maintained at the highest possible dose when managing AEs. To conclude, lenvatinib-associated AEs can be managed with prophylactic measures, regular monitoring and symptomatic management, which can ensure continued treatment and maximum survival benefit in patients with advanced HCC receiving first-line lenvatinib therapy.
- | lenvatinib / Generic mfg.
Journal: Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? (Pubmed Central) - Mar 29, 2022
The absence of pharmacologic interactions between classical immunosuppressive drugs and lenvatinib may allow its use as an early adjuvant approach when the risk of recurrence is high. The strength of our case consists in the long follow-up and the innovative message allowing changing palliative strategies into curative ones in case of advanced HEHE.
- | lenvatinib / Generic mfg.
Journal: Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma. (Pubmed Central) - Mar 29, 2022
The strength of our case consists in the long follow-up and the innovative message allowing changing palliative strategies into curative ones in case of advanced HEHE. Differences in the intestinal microbiomes and their functions may influence the incidence of diarrhea during lenvatinib treatment.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (clinicaltrials.gov) - Mar 29, 2022
P3, N=827, Active, not recruiting, Sponsor: Eisai Inc.
Differences in the intestinal microbiomes and their functions may influence the incidence of diarrhea during lenvatinib treatment. Trial completion date: Nov 2023 --> Jan 2023
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: LENVOS: Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (clinicaltrials.gov) - Mar 29, 2022
P2, N=35, Recruiting, Sponsor: Centre Leon Berard
Trial completion date: Nov 2023 --> Jan 2023 Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- || K1-70 / AV7 Limited
Clinical, Journal: Blocking the TSH receptor with K1-70™ in a patient with follicular thyroid cancer, Graves' disease and Graves' ophthalmopathy. (Pubmed Central) - Mar 26, 2022
On K1-70™ monotherapy during the pause in lenvatinib several metastatic lesions stabilised while others showed progression attenuation compared to that prior to lenvatinib therapy. Conclusions These observations suggest that blocking TSHR stimulation with K1-70™ can be an effective treatment for GO and may also benefit select patients with FTC and GD.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, Real-world evidence: Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. (Pubmed Central) - Mar 26, 2022
The PFS and 6-month survival rate in patients treated with lenvatinib und pazopanib appear to compare favourably to sorafenib in the first line setting. However, more advanced disease stage at treatment initiation in sorafenib- and pazopanib-treated patients in the era prior to TKI-approval and the retrospective nature of this study precludes a direct comparison of TKIs.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Review, Journal: Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers. (Pubmed Central) - Mar 26, 2022
Sorafenib-tosylate, Doxorubicin-hydrochloride, Vandetanib, Cabozantinib-s-malate, Dabrafenib-mesylate, Trametinib-dimethyl-sulfoxide, Lenvatinib-mesylate, Pralsetinib and Selpercatinib are validated for TC treatment...On the basis of this analysis, BM taxonomies should have common standards internationally recognized. BMs show different efficiencies depending on their diagnostic or therapeutic use.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. (Pubmed Central) - Mar 26, 2022
TKIs were associated with better survival outcomes in patients who underwent surgery or WBRT for brain metastasis of HCC and did not increase intracranial bleeding. Therefore, TKIs are efficacious and safe for treating brain metastasis of HCC.
- || Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Clinical, Journal: Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. (Pubmed Central) - Mar 25, 2022
NASH has been identified as an independent prognostic factor in a large cohort of patients with advanced HCC treated with lenvatinib, thereby suggesting the role of the etiology in the selection of patients for tyrosine kinase treatment. If validated, this result could provide new insights useful to improve the management of these patients.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
P3 data, Journal: Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. (Pubmed Central) - Mar 25, 2022
P3
If validated, this result could provide new insights useful to improve the management of these patients. LEAP-012 will evaluate the clinical benefit of adding lenvatinib plus pembrolizumab to TACE in patients with intermediate-stage HCC not amenable to curative treatment.
- | Avastin (bevacizumab) / Roche, IBI-323 / Innovent Biologics, Alecensa (alectinib) / Roche
Biomarker, New P2 trial: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov) - Mar 25, 2022
P2, N=80, Not yet recruiting, Sponsor: Hunan Province Tumor Hospital
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, IO biomarker: Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer (clinicaltrials.gov) - Mar 25, 2022
P2, N=31, Not yet recruiting, Sponsor: Elizabeth K. Lee MD
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), simridarlimab (IBI-322) / Innovent Biologics
Biomarker, New P2 trial: Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2022
P2, N=40, Not yet recruiting, Sponsor: Hunan Province Tumor Hospital
- ||||| Clinical: ICYMI: A phase 3 clinical trial will compare the safety of pembro & quavonlimab + lenvatinib, & that of pembrolizumab, belzutifan, & lenvatinib, vs pembrolizumab/lenvatinib alone in the frontline treatment of advanced RCC @DrChoueiri @DanaFarber #kcsm https://t.co/7e3RLkAuUi (Twitter) - Mar 24, 2022
- || GI-101 / GI Innovation
Trial completion date, Trial primary completion date, Metastases: KEYNOTE-B59: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Mar 24, 2022
P1/2, N=374, Recruiting, Sponsor: GI Innovation, Inc.
LEAP-012 will evaluate the clinical benefit of adding lenvatinib plus pembrolizumab to TACE in patients with intermediate-stage HCC not amenable to curative treatment. Trial completion date: Dec 2025 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Novel Fibroblast Activation Protein Inhibitor-Based targeted Theranostics for Radioiodine Refractory differentiated Thyroid Cancer Patients: A Pilot Study. (Pubmed Central) - Mar 23, 2022
Trial completion date: Dec 2025 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 This preliminary data suggest novel molecule [177Lu]Lu-DOTAGA.(SA.FAPi)2 is safe; seems effective, and most importantly opens up a new avenue for the treatment of aggressive RR-DTC patients who have exhausted all standard line of treatments.
- | lenvatinib / Generic mfg.
Journal, Combination therapy, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: Lenvatinib plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. (Pubmed Central) - Mar 23, 2022
While the immune-modulating potential of lenvatinib is encouraging, alterations in the immune milieu and T cell activation status were insufficient to sustain durable tumor regression, even with added anti-PD-1. Additional studies are necessary to develop more effective combination approaches in low-mutation burden tumors, such as thyroid cancer.
- ||| lenvatinib / Generic mfg.
Journal, Adverse events: Cortisol deficiency in Lenvatinib treatment of thyroid cancer: an underestimated, common adverse event. (Pubmed Central) - Mar 23, 2022
In this context, early diagnosis of PAI is essential, especially since glucocorticoid replacement therapy can induce a significant improvement in fatigue, without the need to reduce the dosage of lenvatinib. However, further studies are required to confirm these preliminary findings.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Heterogeneity, IO biomarker: Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. (Pubmed Central) - Mar 23, 2022
Nude mice are a superior platform than NSG mice for generating PDXs from gastric cancer patients. Lenvatinib showed promising antitumor activity in PDXs established from a diverse Western patient population and warrants further investigation in gastric cancer.
- | lenvatinib / Generic mfg.
Journal: Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. (Pubmed Central) - Mar 23, 2022
Lenvatinib which was individualized based on the patient's weight has promising clinical activity against advanced BTC and had an acceptable safety profile. Additionally, serum biomarkers and gene sequencing may hold the potential to guide our treatment.
- Keytruda (pembrolizumab) / Merck (MSD)
FATAL CARDIAC ARRHYTHMIAS SECONDARY TO PEMBROLIZUMAB TREATMENT ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1287;
Close outpatient monitoring and weekly testing of cardiac troponin and creatine kinase for the first 4 weeks of therapy may be beneficial. It is unclear if there are any predisposing factors to these adverse effects and further research may help oncologists risk stratify such patients.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Phase classification: Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT (clinicaltrials.gov) - Mar 22, 2022
P1, N=20, Recruiting, Sponsor: Beijing Tsinghua Chang Gung Hospital
It is unclear if there are any predisposing factors to these adverse effects and further research may help oncologists risk stratify such patients. Not yet recruiting --> Recruiting | Phase classification: P2 --> P1
- || Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: Pembro-Lenva toxicities is no joke at all (>grade 3 in 89% patients) (Twitter) - Mar 22, 2022
- |||| pimurutamab (HLX07) / Fosun Pharma
New P2 trial: HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 21, 2022
P2, N=60, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors (clinicaltrials.gov) - Mar 21, 2022
P2, N=20, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
I have been using much more ICI mono than PARPi for ARID1A and apart from BRAFi/MEKi, not been using combos much (well, some len/pembro...). Maybe time to reconsider my approach. CUP oncology is classic precision oncology and CUPs deserve much more attention than they get. (Twitter) - Mar 21, 2022
- || lenvatinib / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. (Pubmed Central) - Mar 19, 2022
Our results confirmed that lenvatinib is capable of improving patients' immune status, saving the effector cells from exhaustion status and inhibiting the number and function of immunosuppressive cells. The novel index CTL/Treg ratio qualifies as a predictor for the outcome of patients with lenvatinib therapy.
- | Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Journal, PD(L)-1 Biomarker: Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. (Pubmed Central) - Mar 19, 2022
The novel index CTL/Treg ratio qualifies as a predictor for the outcome of patients with lenvatinib therapy. The mG8 score may contribute to making a decision when considering either sorafenib or lenvatinib as a treatment option for u-HCC in elderly patients.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal, PD(L)-1 Biomarker, IO biomarker: Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. (Pubmed Central) - Mar 18, 2022
Furthermore, preliminary studies have evaluated dabrafenib, and vemurafenib in BRAF mutated RAI-TC patients to re-induce 131-iodine uptake...A new strategy is to combine TKIs with immunotherapy. Several studies are evaluating lenvatinib and pembrolizumab in RAI-TC patients.
- ||||| lenvatinib / Generic mfg.
Clinical: A revamped dose exchange program can allow for dose reduction of lenvatinib without a higher cost to patients and the system - @EmelineAvikiMD changing practice in REAL TIME at @SGO_org #SGOMtg #SGO2022 #gyncsm (Twitter) - Mar 18, 2022
- | New trial: International Multicentric Study ARON-1 (clinicaltrials.gov) - Mar 17, 2022
P=N/A, N=1220, Not yet recruiting, Sponsor: Hospital of Macerata
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov) - Mar 17, 2022
P2, N=40, Not yet recruiting, Sponsor: National Cancer Centre, Singapore
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. (clinicaltrials.gov) - Mar 17, 2022
P1/2, N=27, Not yet recruiting, Sponsor: National Taiwan University Hospital
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) (clinicaltrials.gov) - Mar 17, 2022
P3, N=405, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Several studies are evaluating lenvatinib and pembrolizumab in RAI-TC patients. Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: LEAP-007 China Extension: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na (clinicaltrials.gov) - Mar 17, 2022
P3, N=27, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial completion date: Nov 2025 --> Nov 2023
- lenvatinib / Generic mfg.
Patient-derived hepatocellular carcinoma organoids as predictors of Treatment Response (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1591;
Trial completion date: Nov 2025 --> Nov 2023 Our results demonstrated that HCOs with specific structural features provide platform to identify the relationship between drug response and CSC-related signal in HCC.
- lenvatinib / Generic mfg.
Role of autophagy-mediated neuropilin-1 degradation on lenvatinib efficacy in human hepatocarcinoma (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1166;
Our results demonstrated that HCOs with specific structural features provide platform to identify the relationship between drug response and CSC-related signal in HCC. Autophagy-dependent NRP1 degradation seems to play a key role in lenvatinib efficacy in HCC, highlighting the potential interest of NRP1 silencing as a novel strategy to prevent therapeutic failure in advanced HCC.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Potential faesability of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma: a real-world analysis (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_845;
These patients have a better OS than noneligible ones, owing to a better baseline clinical profile. Therefore, TKIs will remain the front-line approach for most of the HCC patients qualified for systemic therapy, due to the stringent selection criteria dictated by immunotherapy trials and the use of TKIs currently extended to Child-Pugh B patients.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
The efficacy of molecular targeted therapies after atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) in Japan (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_838;
Discontinuation of atez+bev due to adverse events in real-world practice was similar to the clinical trial, and all patients with pretreatment PS 0 and modified ALBI 1 or 2a could receive postatez+ bev therapies after disease progression. The efficacy of molecular targeted agents after atez+bev would be different from the results of the past clinical trials without immunotherapy.
- | Nexavar (sorafenib) / Bayer, Amgen
Preclinical, Journal: Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo. (Pubmed Central) - Mar 16, 2022
We also found both protein kinase C delta (PKC-δ) and p38 mitogen-activated protein kinase (MAPK) inactivation participated in lenvatinib-reduced NF-κB signaling. In conclusion, this study reveals that the suppression of PKC-δ, and the p38 MAPK/NF-κB axis is associated with the lenvatinib-inhibited progression of HCC in vitro and in vivo.
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
remarkable work from @AarmstrongDuke @Daniel_J_George and @DukeGUCancer Pls support the combination trial of lenvatinib and pembro through HCRN in NEPC and aggressive variant prostate cancer (Twitter) - Mar 16, 2022